ID   FAK2_HUMAN              Reviewed;        1009 AA.
AC   Q14289; Q13475; Q14290; Q16709;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   02-NOV-2010, entry version 128.
DE   RecName: Full=Protein-tyrosine kinase 2-beta;
DE            EC=2.7.10.2;
DE   AltName: Full=Calcium-dependent tyrosine kinase;
DE            Short=CADTK;
DE   AltName: Full=Cell adhesion kinase beta;
DE            Short=CAK-beta;
DE   AltName: Full=Focal adhesion kinase 2;
DE            Short=FADK 2;
DE   AltName: Full=Proline-rich tyrosine kinase 2;
DE   AltName: Full=Related adhesion focal tyrosine kinase;
DE            Short=RAFTK;
GN   Name=PTK2B; Synonyms=FAK2, PYK2, RAFTK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   MEDLINE=95379967; PubMed=7544443; DOI=10.1038/376737a0;
RA   Lev S., Moreno H., Martinez R., Canoll P., Peles E., Musacchio J.M.,
RA   Plowman G.D., Rudy B., Schlessinger J.;
RT   "Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of
RT   ion channel and MAP kinase functions.";
RL   Nature 376:737-745(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus;
RX   MEDLINE=96435932; PubMed=8838818; DOI=10.1006/geno.1996.0149;
RA   Herzog H., Nicholl J., Hort Y.J., Sutherland G.R., Shine J.;
RT   "Molecular cloning and assignment of FAK2, a novel human focal
RT   adhesion kinase, to 8p11.2-p22 by nonisotopic in situ hybridization.";
RL   Genomics 32:484-486(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus;
RX   MEDLINE=95403356; PubMed=7673154; DOI=10.1074/jbc.270.36.21206;
RA   Sasaki H., Nagura K., Ishino M., Tobioka H., Kotani K., Sasaki T.;
RT   "Cloning and characterization of cell adhesion kinase beta, a novel
RT   protein-tyrosine kinase of the focal adhesion kinase subfamily.";
RL   J. Biol. Chem. 270:21206-21219(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   MEDLINE=96070905; PubMed=7499242; DOI=10.1074/jbc.270.46.27742;
RA   Avraham S., London R., Fu Y., Ota S., Hiregowdara D., Li J., Jiang S.,
RA   Pasztor L.M., White R.A., Groopman J.E., Avraham H.;
RT   "Identification and characterization of a novel related adhesion focal
RT   tyrosine kinase (RAFTK) from megakaryocytes and brain.";
RL   J. Biol. Chem. 270:27742-27751(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Monocyte;
RX   MEDLINE=98211954; PubMed=9545257; DOI=10.1074/jbc.273.16.9361;
RA   Li X., Hunter D., Morris J., Haskill J.S., Earp H.S.;
RT   "A calcium-dependent tyrosine kinase splice variant in human
RT   monocytes. Activation by a two-stage process involving adherence and a
RT   subsequent intracellular signal.";
RL   J. Biol. Chem. 273:9361-9364(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INTERACTION WITH TGFB1I1.
RX   MEDLINE=98086276; PubMed=9422762; DOI=10.1074/jbc.273.2.1003;
RA   Matsuya M., Sasaki H., Aoto H., Mitaka T., Nagura K., Ohba T.,
RA   Ishino M., Takahashi S., Suzuki R., Sasaki T.;
RT   "Cell adhesion kinase beta forms a complex with a new member, Hic-5,
RT   of proteins localized at focal adhesions.";
RL   J. Biol. Chem. 273:1003-1014(1998).
RN   [9]
RP   INTERACTION WITH ASAP2.
RX   MEDLINE=99147068; PubMed=10022920;
RA   Andreev J., Simon J.-P., Sabatini D.D., Kam J., Plowman G.,
RA   Randazzo P.A., Schlessinger J.;
RT   "Identification of a new Pyk2 target protein with Arf-GAP activity.";
RL   Mol. Cell. Biol. 19:2338-2350(1999).
RN   [10]
RP   PHOSPHORYLATION AT TYR-402, MUTAGENESIS OF PRO-859, AND INTERACTION
RP   WITH NEPHROCYSTIN.
RX   MEDLINE=21396557; PubMed=11493697; DOI=10.1073/pnas.171269898;
RA   Benzing T., Gerke P., Hoepker K., Hildebrandt F., Kim E., Walz G.;
RT   "Nephrocystin interacts with Pyk2, p130(Cas), and tensin and triggers
RT   phosphorylation of Pyk2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:9784-9789(2001).
RN   [11]
RP   INTERACTION WITH SKAP2, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=12893833; DOI=10.1074/jbc.M213217200;
RA   Takahashi T., Yamashita H., Nagano Y., Nakamura T., Ohmori H.,
RA   Avraham H., Avraham S., Yasuda M., Matsumoto M.;
RT   "Identification and characterization of a novel Pyk2/related adhesion
RT   focal tyrosine kinase-associated protein that inhibits alpha-synuclein
RT   phosphorylation.";
RL   J. Biol. Chem. 278:42225-42233(2003).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-579 AND TYR-580, AND
RP   MASS SPECTROMETRY.
RX   MEDLINE=22426906; PubMed=12522270; DOI=10.1073/pnas.2436191100;
RA   Salomon A.R., Ficarro S.B., Brill L.M., Brinker A., Phung Q.T.,
RA   Ericson C., Sauer K., Brock A., Horn D.M., Schultz P.G., Peters E.C.;
RT   "Profiling of tyrosine phosphorylation pathways in human cells using
RT   mass spectrometry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:443-448(2003).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-579 AND TYR-580, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-375 AND TYR-579, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-580, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=17389395; DOI=10.1073/pnas.0608638104;
RA   Wolf-Yadlin A., Hautaniemi S., Lauffenburger D.A., White F.M.;
RT   "Multiple reaction monitoring for robust quantitative proteomic
RT   analysis of cellular signaling networks.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:5860-5865(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-375, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-375; SER-399; SER-758;
RP   SER-762; THR-765; SER-839 AND THR-842, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-579 AND TYR-580, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Mammary epithelium;
RX   PubMed=19534553; DOI=10.1021/pr900044c;
RA   Heibeck T.H., Ding S.-J., Opresko L.K., Zhao R., Schepmoes A.A.,
RA   Yang F., Tolmachev A.V., Monroe M.E., Camp D.G. II, Smith R.D.,
RA   Wiley H.S., Qian W.-J.;
RT   "An extensive survey of tyrosine phosphorylation revealing new sites
RT   in human mammary epithelial cells.";
RL   J. Proteome Res. 8:3852-3861(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; THR-15; SER-361;
RP   SER-375; SER-389; SER-392; SER-394; SER-396; SER-399; SER-559;
RP   TYR-579; TYR-580; SER-583; TYR-722; SER-746; SER-762; SER-778;
RP   TYR-819; TYR-834; SER-839; TYR-849; SER-866 AND THR-966, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLU-359; HIS-698; PRO-808; THR-838 AND
RP   LYS-970.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Involved in calcium induced regulation of ion channel
CC       and activation of the map kinase signaling pathway. May represent
CC       an important signaling intermediate between neuropeptide activated
CC       receptors or neurotransmitters that increase calcium flux and the
CC       downstream signals that regulate neuronal activity. Interacts with
CC       the SH2 domain of Grb2. May phosphorylate the voltage-gated
CC       potassium channel protein Kv1.2. Its activation is highly
CC       correlated with the stimulation of c-Jun N-terminal kinase
CC       activity. Involved in osmotic stress-dependent SNCA 'Tyr-125'
CC       phosphorylation.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Interacts with Crk-associated substrate (Cas), PTPNS1 and
CC       SH2D3C (By similarity). Interacts with nephrocystin, ASAP2,
CC       OPHN1L, SKAP2 and TGFB1I1.
CC   -!- INTERACTION:
CC       Q7L0Q8:RHOU; NbExp=4; IntAct=EBI-298640, EBI-1638043;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Note=Interaction
CC       with nephrocystin induces the membrane-association of the kinase.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q14289-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q14289-2; Sequence=VSP_004981;
CC   -!- TISSUE SPECIFICITY: Most abundant in the brain, with highest
CC       levels in amygdala and hippocampus. Low levels in kidney. Also
CC       expressed in spleen and lymphocytes.
CC   -!- PTM: Phosphorylated on tyrosine residues in response to various
CC       stimuli that elevate the intracellular calcium concentration, as
CC       well as by PKC activation. Recruitment by nephrocystin to cell
CC       matrix adhesions initiates Tyr-402 phosphorylation. In monocytes,
CC       adherence to substrata is required for tyrosine phosphorylation
CC       and kinase activation. Angiotensin II, thapsigargin and L-alpha-
CC       lysophosphatidic acid (LPA) also induce autophosphorylation and
CC       increase kinase activity (By similarity).
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. FAK subfamily.
CC   -!- SIMILARITY: Contains 1 FERM domain.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U33284; AAC50203.1; -; mRNA.
DR   EMBL; L49207; AAB47217.1; -; mRNA.
DR   EMBL; D45853; BAA08289.1; -; mRNA.
DR   EMBL; U43522; AAC05330.1; -; mRNA.
DR   EMBL; S80542; AAB35701.1; -; mRNA.
DR   EMBL; AF311103; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC042599; AAH42599.1; -; mRNA.
DR   IPI; IPI00029702; -.
DR   IPI; IPI00216435; -.
DR   PIR; S60248; S60248.
DR   RefSeq; NP_004094.3; -.
DR   RefSeq; NP_775266.1; -.
DR   RefSeq; NP_775267.1; -.
DR   RefSeq; NP_775268.1; -.
DR   UniGene; Hs.491322; -.
DR   PDB; 2FO6; Model; -; X=45-350.
DR   PDB; 3CC6; X-ray; 1.60 A; A=414-692.
DR   PDB; 3ET7; X-ray; 2.70 A; A=416-692.
DR   PDB; 3FZO; X-ray; 2.20 A; A=416-692.
DR   PDB; 3FZP; X-ray; 2.10 A; A=416-692.
DR   PDB; 3FZR; X-ray; 2.70 A; A=416-692.
DR   PDB; 3FZS; X-ray; 1.75 A; A=416-692.
DR   PDB; 3FZT; X-ray; 1.95 A; A=416-692.
DR   PDB; 3GM1; X-ray; 2.95 A; A/B=861-1009.
DR   PDB; 3GM2; X-ray; 2.71 A; A=861-1009.
DR   PDB; 3GM3; X-ray; 2.60 A; A=861-1009.
DR   PDB; 3H3C; X-ray; 2.00 A; A=416-692.
DR   PDBsum; 2FO6; -.
DR   PDBsum; 3CC6; -.
DR   PDBsum; 3ET7; -.
DR   PDBsum; 3FZO; -.
DR   PDBsum; 3FZP; -.
DR   PDBsum; 3FZR; -.
DR   PDBsum; 3FZS; -.
DR   PDBsum; 3FZT; -.
DR   PDBsum; 3GM1; -.
DR   PDBsum; 3GM2; -.
DR   PDBsum; 3GM3; -.
DR   PDBsum; 3H3C; -.
DR   ProteinModelPortal; Q14289; -.
DR   SMR; Q14289; 56-355.
DR   IntAct; Q14289; 16.
DR   MINT; MINT-1211326; -.
DR   STRING; Q14289; -.
DR   PhosphoSite; Q14289; -.
DR   PRIDE; Q14289; -.
DR   Ensembl; ENST00000346049; ENSP00000332816; ENSG00000120899.
DR   Ensembl; ENST00000397501; ENSP00000380638; ENSG00000120899.
DR   Ensembl; ENST00000420218; ENSP00000391995; ENSG00000120899.
DR   GeneID; 2185; -.
DR   KEGG; hsa:2185; -.
DR   UCSC; uc003xfn.1; human.
DR   UCSC; uc003xfq.1; human.
DR   CTD; 2185; -.
DR   GeneCards; GC08P027224; -.
DR   H-InvDB; HIX0025557; -.
DR   HGNC; HGNC:9612; PTK2B.
DR   HPA; CAB003850; -.
DR   HPA; HPA026091; -.
DR   HPA; HPA026276; -.
DR   MIM; 601212; gene.
DR   PharmGKB; PA33956; -.
DR   eggNOG; prNOG16400; -.
DR   HOGENOM; HBG444482; -.
DR   HOVERGEN; HBG004018; -.
DR   InParanoid; Q14289; -.
DR   OMA; DQETYRC; -.
DR   OrthoDB; EOG9R26F1; -.
DR   PhylomeDB; Q14289; -.
DR   BRENDA; 2.7.10.2; 247.
DR   Pathway_Interaction_DB; alphasynuclein_pathway; Alpha-synuclein signaling.
DR   Pathway_Interaction_DB; ar_pathway; Coregulation of Androgen receptor activity.
DR   Pathway_Interaction_DB; endothelinpathway; Endothelins.
DR   Pathway_Interaction_DB; fgf_pathway; FGF signaling pathway.
DR   Pathway_Interaction_DB; il2_1pathway; IL2-mediated signaling events.
DR   Pathway_Interaction_DB; avb3_integrin_pathway; Integrins in angiogenesis.
DR   Pathway_Interaction_DB; lysophospholipid_pathway; LPA receptor mediated events.
DR   Pathway_Interaction_DB; avb3_opn_pathway; Osteopontin-mediated events.
DR   Pathway_Interaction_DB; met_pathway; Signaling events activated by Hepatocyte Growth Factor Receptor (c-Met).
DR   Pathway_Interaction_DB; vegfr1_2_pathway; Signaling events mediated by VEGFR1 and VEGFR2.
DR   NextBio; 8821; -.
DR   ArrayExpress; Q14289; -.
DR   Bgee; Q14289; -.
DR   CleanEx; HS_PTK2B; -.
DR   Genevestigator; Q14289; -.
DR   GermOnline; ENSG00000120899; Homo sapiens.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kina...; TAS:ProtInc.
DR   GO; GO:0004871; F:signal transducer activity; NAS:ProtInc.
DR   GO; GO:0006915; P:apoptosis; TAS:ProtInc.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0007172; P:signal complex assembly; TAS:ProtInc.
DR   InterPro; IPR019749; Band_41_domain.
DR   InterPro; IPR014352; FERM/acyl-CoA-bd_prot_3-hlx.
DR   InterPro; IPR019748; FERM_central.
DR   InterPro; IPR000299; FERM_domain.
DR   InterPro; IPR005189; Focal_adhesion_kin_target_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR020773; Tyr_kinase_non-rcpt_FADK.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   Gene3D; G3DSA:1.20.80.10; ACBP; 1.
DR   PANTHER; PTHR23256:SF277; Tyr_kinase_non-rcpt_FADK; 1.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   Pfam; PF00373; FERM_M; 1.
DR   Pfam; PF03623; Focal_AT; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   ProDom; PD006413; Focal_adhesion_target_reg; 1.
DR   SMART; SM00295; B41; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47031; FERM_3-hlx; 1.
DR   SUPFAM; SSF68993; Focal_AT; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00660; FERM_1; FALSE_NEG.
DR   PROSITE; PS00661; FERM_2; FALSE_NEG.
DR   PROSITE; PS50057; FERM_3; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Cytoplasm; Kinase; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Transferase; Tyrosine-protein kinase.
FT   CHAIN         1   1009       Protein-tyrosine kinase 2-beta.
FT                                /FTId=PRO_0000088081.
FT   DOMAIN       39    359       FERM.
FT   DOMAIN      425    683       Protein kinase.
FT   NP_BIND     431    439       ATP (By similarity).
FT   REGION      801   1009       Interaction with TGFB1I1 (By similarity).
FT   REGION      868   1009       Focal adhesion targeting (FAT).
FT   COMPBIAS    702    767       Pro-rich.
FT   COMPBIAS    831    869       Pro-rich.
FT   ACT_SITE    549    549       Proton acceptor (By similarity).
FT   BINDING     457    457       ATP (By similarity).
FT   MOD_RES       2      2       Phosphoserine.
FT   MOD_RES      15     15       Phosphothreonine.
FT   MOD_RES     361    361       Phosphoserine.
FT   MOD_RES     375    375       Phosphoserine.
FT   MOD_RES     389    389       Phosphoserine.
FT   MOD_RES     392    392       Phosphoserine.
FT   MOD_RES     394    394       Phosphoserine.
FT   MOD_RES     396    396       Phosphoserine.
FT   MOD_RES     399    399       Phosphoserine.
FT   MOD_RES     402    402       Phosphotyrosine.
FT   MOD_RES     440    440       Phosphotyrosine (By similarity).
FT   MOD_RES     559    559       Phosphoserine.
FT   MOD_RES     579    579       Phosphotyrosine; by autocatalysis.
FT   MOD_RES     580    580       Phosphotyrosine.
FT   MOD_RES     583    583       Phosphoserine.
FT   MOD_RES     722    722       Phosphotyrosine.
FT   MOD_RES     746    746       Phosphoserine.
FT   MOD_RES     758    758       Phosphoserine.
FT   MOD_RES     762    762       Phosphoserine.
FT   MOD_RES     765    765       Phosphothreonine.
FT   MOD_RES     778    778       Phosphoserine.
FT   MOD_RES     819    819       Phosphotyrosine.
FT   MOD_RES     834    834       Phosphotyrosine.
FT   MOD_RES     839    839       Phosphoserine.
FT   MOD_RES     842    842       Phosphothreonine.
FT   MOD_RES     849    849       Phosphotyrosine.
FT   MOD_RES     866    866       Phosphoserine.
FT   MOD_RES     881    881       Phosphotyrosine (By similarity).
FT   MOD_RES     966    966       Phosphothreonine.
FT   VAR_SEQ     739    780       Missing (in isoform 2).
FT                                /FTId=VSP_004981.
FT   VARIANT     359    359       Q -> E (in dbSNP:rs56175011).
FT                                /FTId=VAR_041687.
FT   VARIANT     698    698       R -> H (in dbSNP:rs35174236).
FT                                /FTId=VAR_041688.
FT   VARIANT     808    808       L -> P (in dbSNP:rs55747955).
FT                                /FTId=VAR_041689.
FT   VARIANT     838    838       K -> T (in dbSNP:rs751019).
FT                                /FTId=VAR_020284.
FT   VARIANT     970    970       E -> K (in dbSNP:rs56263944).
FT                                /FTId=VAR_041690.
FT   MUTAGEN     859    859       P->A: Loss of interaction with
FT                                nephrocystin.
FT   CONFLICT     23     23       A -> G (in Ref. 3; BAA08289/AAC05330).
FT   CONFLICT    256    256       G -> P (in Ref. 2; AAB47217).
FT   CONFLICT    435    435       F -> L (in Ref. 3; AAC05330).
FT   CONFLICT    780    780       R -> G (in Ref. 2; AAB47217).
FT   HELIX       422    424
FT   STRAND      425    433
FT   STRAND      435    445
FT   STRAND      451    458
FT   HELIX       465    481
FT   STRAND      489    493
FT   STRAND      495    497
FT   STRAND      499    503
FT   HELIX       510    517
FT   TURN        518    520
FT   HELIX       523    542
FT   HELIX       552    554
FT   STRAND      555    559
FT   STRAND      562    565
FT   HELIX       570    572
FT   HELIX       589    591
FT   HELIX       594    599
FT   HELIX       604    619
FT   TURN        620    622
FT   TURN        625    628
FT   HELIX       631    633
FT   HELIX       634    640
FT   HELIX       652    661
FT   HELIX       666    668
FT   HELIX       672    691
SQ   SEQUENCE   1009 AA;  115875 MW;  420B21046274E7C2 CRC64;
     MSGVSEPLSR VKLGTLRRPE GPAEPMVVVP VDVEKEDVRI LKVCFYSNSF NPGKNFKLVK
     CTVQTEIREI ITSILLSGRI GPNIRLAECY GLRLKHMKSD EIHWLHPQMT VGEVQDKYEC
     LHVEAEWRYD LQIRYLPEDF MESLKEDRTT LLYFYQQLRN DYMQRYASKV SEGMALQLGC
     LELRRFFKDM PHNALDKKSN FELLEKEVGL DLFFPKQMQE NLKPKQFRKM IQQTFQQYAS
     LREEECVMKF FNTLAGFANI DQETYRCELI QGWNITVDLV IGPKGIRQLT SQDAKPTCLA
     EFKQIRSIRC LPLEEGQAVL QLGIEGAPQA LSIKTSSLAE AENMADLIDG YCRLQGEHQG
     SLIIHPRKDG EKRNSLPQIP MLNLEARRSH LSESCSIESD IYAEIPDETL RRPGGPQYGI
     AREDVVLNRI LGEGFFGEVY EGVYTNHKGE KINVAVKTCK KDCTLDNKEK FMSEAVIMKN
     LDHPHIVKLI GIIEEEPTWI IMELYPYGEL GHYLERNKNS LKVLTLVLYS LQICKAMAYL
     ESINCVHRDI AVRNILVASP ECVKLGDFGL SRYIEDEDYY KASVTRLPIK WMSPESINFR
     RFTTASDVWM FAVCMWEILS FGKQPFFWLE NKDVIGVLEK GDRLPKPDLC PPVLYTLMTR
     CWDYDPSDRP RFTELVCSLS DVYQMEKDIA MEQERNARYR TPKILEPTAF QEPPPKPSRP
     KYRPPPQTNL LAPKLQFQVP EGLCASSPTL TSPMEYPSPV NSLHTPPLHR HNVFKRHSMR
     EEDFIQPSSR EEAQQLWEAE KVKMRQILDK QQKQMVEDYQ WLRQEEKSLD PMVYMNDKSP
     LTPEKEVGYL EFTGPPQKPP RLGAQSIQPT ANLDRTDDLV YLNVMELVRA VLELKNELCQ
     LPPEGYVVVV KNVGLTLRKL IGSVDDLLPS LPSSSRTEIE GTQKLLNKDL AELINKMRLA
     QQNAVTSLSE ECKRQMLTAS HTLAVDAKNL LDAVDQAKVL ANLAHPPAE
//
